MichaelAndreeffMDPhD

PubMed

• Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.
  Elias Jabbour, Fadi G Haddad, Koji Sasaki, Bing Z Carter, Yesid Alvarado, Cedric Nasnas, Lewis Nasr, Lucia Masarova, Naval Daver, Naveen Pemmaraju, Nicholas J Short, J...> ;Cancer. 2024 Apr 9
• Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study.
  Prithviraj Bose, Lucia Masarova, Naveen Pemmaraju, Sharon D Bledsoe, Naval G Daver, Elias J Jabbour, Tapan M Kadia, Zeev Estrov, Steven M Kornblau, Michael Andreeff, N...> ;Haematologica. 2024 Apr 4
• Correction: Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia.
  Hiroki Akiyama, Ran Zhao, Lauren B Ostermann, Ziyi Li, Matthew Tcheng, Samar J Yazdani, Arman Moayed, Malcolm L Pryor 2nd, Sandeep Slngh, Natalia Baran, Edward Ayoub, ...> ;Leukemia. 2024 Apr 1
• Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial.
  Konopleva, M., Dail, M., Daver, N., Garcia, J., Jonas, B., Yee, K., Kelly, K., Vey, N., Assouline, S., Roboz, G., Paolini, S., Pollyea, D., Tafuri, A., Brandwein, J., ...> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Jan 18
• Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia.
  Hiroki Akiyama, Ran Zhao, Lauren B Ostermann, Ziyi Li, Matthew Tcheng, Samar J Yazdani, Arman Moayed, Malcolm L Pryor 2nd, Sandeep Slngh, Natalia Baran, Edward Ayoub, ...> ;Leukemia. 2024 Apr 1
• 1 citations
  Enhancedreactivation disruptstranscriptional program and overcomes venetoclax resistance in acute myeloid leukemias.
  Yuki Nishida, Jo Ishizawa, Edward Ayoub, Rafael Heinz Montoya, Lauren B Ostermann, Muharrem Muftuoglu, Vivian R Ruvolo, Tallie Patsilevas, Darah A Scruggs, Shayaun Kha...> ;Science Advances. 2023 Dec 1
• 2 citations
  ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia.
  Jessica Ebner, Johannes Schmoellerl, Martin Piontek, Gabriele Manhart, Selina Troester, Bing Z Carter, Heidi Neubauer, Richard Moriggl, Gergely Szakács, Johannes Zuber...> ;Nature Communications. 2023 Sep 19
• Cigarette smoke exposure accelerates AML progression in FLT3-ITD models.
  Mary Figueroa, Huaxian Ma, Mansour Alfayez, Daniel Enrique Morales-Mantilla, Fei Wang, Yue Lu, Marcos R Estecio, Katherine Y King, Eugenie Kleinerman, Seyed Javad Mogh...> ;Blood Advances. 2023 Nov 14
• 8 citations
  A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.
  Nicholas J Short, Muharrem Muftuoglu, Faustine Ong, Lewis Nasr, Walid Macaron, Guillermo Montalban-Bravo, Yesid Alvarado, Mahesh Basyal, Naval Daver, Courtney D Dinard...> ;Journal of Hematology & Oncology. 2023 Jul 8
• 3 citations
  A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and c...
  Jayastu Senapati, Muharrem Muftuoglu, Jo Ishizawa, Hussein A Abbas, Sanam Loghavi, Gautam Borthakur, Musa Yilmaz, Ghayas C Issa, Samuel I Dara, Mahesh Basyal, Li Li, K...> ;Blood Cancer Journal. 2023 Jun 29
• Mdm2/p53 levels in bone marrow mesenchymal stromal cells are essential for maintaining the hematopoietic niche in response to DNA damage.
  Rasoul Pourebrahim, Rafael Heinz Montoya, Zoe Alaniz, Lauren Ostermann, Patrick P Lin, Bin Liu, Edward Ayoub, Jared K Burks, Michael Andreeff> ;Cell Death & Disease. 2023 Jun 23
• 4 citations
  Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells.
  Bing Z Carter, Po Yee Mak, Muharrem Muftuoglu, Wenjing Tao, Baozhen Ke, Jingqi Pei, Andrea D Bedoy, Lauren B Ostermann, Yuki Nishida, Sevinj Isgandarova, Mary Sobieski...> ;Blood. 2023 Sep 21
• Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics.
  Bing Z Carter, Po Yee Mak, Wenjing Tao, Edward Ayoub, Lauren B Ostermann, Xuelin Huang, Sanam Loghavi, Steffen Boettcher, Yuki Nishida, Vivian Ruvolo, Paul E Hughes, P...> ;Blood Cancer Journal. 2023 May 17
• 3 citations
  Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia.
  Christina Glytsou, Xufeng Chen, Emmanouil Zacharioudakis, Wafa Al-Santli, Hua Zhou, Bettina Nadorp, Soobeom Lee, Audrey Lasry, Zhengxi Sun, Dimitrios Papaioannou, Mich...> ;Cancer Discovery. 2023 Jul 7
• 4 citations
  Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics.
  Bing Z Carter, Po Yee Mak, Wenjing Tao, Edward Ayoub, Lauren B Ostermann, Xuelin Huang, Sanam Loghavi, Steffen Boettcher, Yuki Nishida, Vivian Ruvolo, Paul E Hughes, P...> ;Blood Cancer Journal. 2023 Apr 24
• 4 citations
  FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-target...
  Yannan Jia, Weiguo Zhang, Mahesh Basyal, Kyung Hee Chang, Lauren Ostermann, Jared K Burks, Charlie Ly, Hong Mu-Mosley, Qi Zhang, Xin Han, William E Fogler, John L Magn...> ;Leukemia. 2023 Jun 1
• 4 citations
  Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells.
  Yannan Jia, Lina Han, Cassandra L Ramage, Zhe Wang, Connie C Weng, Lei Yang, Simona Colla, Helen Ma, Weiguo Zhang, Michael Andreeff, Naval Daver, Nitin Jain, Naveen Pe...> ;Haematologica. 2023 Oct 1
• 8 citations
  Molecular Mechanisms of Ferroptosis and Updates of Ferroptosis Studies in Cancers and Leukemia.
  Hiroki Akiyama, Bing Z Carter, Michael Andreeff, Jo Ishizawa> ;Cells. 2023 Apr 11
• 1 citations
  Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation.
  Daniel Nguyen, Hagop M Kantarjian, Nicholas J Short, Wei Qiao, Jing Ning, Branko Cuglievan, Naval G Daver, Courtney D DiNardo, Elias J Jabbour, Tapan M Kadia, Gautam B...> ;Cancer. 2023 Jun 15
• 8 citations
  Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity.
  Alexandre Bazinet, Tapan Kadia, Nicholas J Short, Gautam Borthakur, Sa A Wang, Wei Wang, Sanam Loghavi, Jeffrey Jorgensen, Keyur Patel, Courtney DiNardo, Naval Daver, ...> ;Blood Advances. 2023 Jul 11
• Mdm2/p53 levels in bone marrow mesenchymal stromal cells is essential for maintaining the hematopoietic niche in response to DNA damage.
  Rasoul Pourebrahim, Rafael Heinz Montoya, Zoe Alaniz, Lauren Ostermann, Patrick P Lin, Bin Liu, Edward Ayoub, Jared K Burks, Michael Andreeff> ;Research Square. 2023 Mar 2
• The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and Aurora kinases.
  Guopan Yu, Weiguo Zhang, Hongying Zhang, Charlie Ly, Mahesh Basyal, William G Rice, Michael Andreeff> ;Research Square. 2023 Feb 22
• 3 citations
  Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia.
  Seemana Bhattacharya, Sujan Piya, Huaxian Ma, Priyanka Sharma, Qi Zhang, Natalia Baran, Vivian R Ruvolo, Teresa McQueen, R Eric Davis, Rasoul Pourebrahim, Marina Konop...> ;Molecular Cancer Research. 2023 Jun 1
• Inhibition of menin, BCL-2, and FLT3 combined with a hypomethylating agent cures-ITD/-TKD mutant acute myeloid leukemia in a patient-derived xenograft model.
  Bing Z Carter, Po Yee Mak, Wenjing Tao, Lauren B Ostermann, Duncan H Mak, Baozhen Ke, Peter Ordentlich, Gerard M McGeehan, Michael Andreeff> ;Haematologica. 2023 Sep 1
• 10 citations
  Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML.
  Ghayas C Issa, Aram Bidikian, Sangeetha Venugopal, Marina Konopleva, Courtney D DiNardo, Tapan M Kadia, Gautam Borthakur, Elias Jabbour, Naveen Pemmaraju, Musa Yilmaz,...> ;Blood Advances. 2023 Mar 28
• Join now to see all

Journal Articles

• Integrative Genomic Analysis of Adult Mixed Phenotype Acute Leukemia Delineates Lineage Associated Molecular Subtypes  
  Koichi Takahashi, Marina Konopleva, Steven Kornblau, Hagop Kantarjian, Nitin Jain, Elias Jabbour, Courtney D DiNardo, Michael Andreeff, Nature
• NSG-S Mice for Acute Myeloid Leukemia, Yes. For Myelodysplastic Syndrome, No  
  Michael Andreeff, MD, Haematologica
• PTEN Status Is a Crucial Determinant of the Functional Outcome of Combined MEK and mTOR Inhibition in Cancer  
  Michael Andreeff, Marina Konopleva, Nature

Abstracts/Posters

• Inhibition of Anti-Apoptotic Mcl-1 Exerts Anti-Leukemia Activity through Modulation of Leukemia-Stromal Interactions and Metabolic Functions in AML
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) ...
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Dual Targeting of Mitochondrial Unfolded Protein Response and BCL2 in Acute Myeloid Leukemia
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• TP73 As Novel Determinant of Resistance to BCL-2 Inhibition in Acute Myeloid Leukemia
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Inhibition of Mcl-1 Enhances the Efficacy of Tyrosine Kinase Inhibition in FLT3 Mutated AML and Synergizes with Venetoclax Targeting AML Stem Cells
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remis...
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Impact of p53 Knock-Down on T-Cell Proliferation and T-Cell Mediated Cytotoxicity Against AML Cell Lines Mediated By a CD33 Specific BiTE¬ Antibody Construct
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Cage Transcriptome Analysis Reveals BCL2A1 Upregulation in FLT3-ITD/D835 Dual Mutated AML Cells Harboring Complex Co-Mutations
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Intravital Imaging of Bright Cyan-Fluorescent AML Model Reveals Impact of CXCR4 Inhibitor on AML and Immune Cell Dynamics
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• TP53 Deficient/Mutant AMLs Are Resistant to Individual BH3 Mimetics: High Efficacy of Combined Inhibition of Bcl-2 and Mcl-1
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Dual Inhibition of MDM2 and XPO1 Synergizes to Induce Apoptosis in Acute Myeloid Leukemia Progenitor Cells with Wild-Type TP53 through Nuclear Accumulation of p53 and ...
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Single-Cell Mapping of Stress Response and Cell Death Pathways in Acute Myeloid Leukemia Reveals Stressor-Specific Alterations and Distinct Response Patterns
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II TrialClinically Relevant Abstract
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Oxphos Inhibition Induces Formation of Tunneling Nanotubes in AML Cells and Facilitates Mitochondrial Transfer from BM Stroma to AML That Contributes to Microenvironme...
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• AXL/Mertk Inhibitor ONO-7475 Potently Synergizes with BCL2 Inhibitor ABT-199, Overcomes ABT-199 Resistance Mechanisms, and Kills FLT3 ITD AML Cells
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Determinants of Outcomes of FLT3mut Acute Myeloid Leukemia with First Salvage Therapy
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• p53 Mediated Bone Marrow Mesenchymal Stem Cell Expansion Supports Acute Myeloid Leukemia Development
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Incidence of Serious Adverse Events, Pneumonitis, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphom...
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Targeting Misfolded p53 and p53 Aggregation to Overcome Resistance to Apoptosis in Acute Myeloid Leukemia 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndr... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Acute Myeloid Leukemia Expands Osteoprogenitor Rich Niche in the Bone Marrow but Resorbs Mature Bone Causing Osteopenia/Osteoporosis in Animal Models 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Targeting Wnt/β-Catenin and BCL-2, Two Critical Survival Factors, Synergistically Induces Apoptosis in AML Via Rac1-Mediated MCL-1 Inhibition 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Single-Cell Atlas of Driver Mutations in Acute Myeloid Leukemia (AML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Diverse Landscape of TET2 Variants in MDS and AML 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all